A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT01865747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Study identification
- NCT ID
- NCT01865747
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 658 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2013 (Type not available)
- Primary completion
- May 22, 2015 (Actual)
- Completion
- Jan 15, 2021 (Actual)
- Last update posted
- Apr 27, 2021
2013 – 2021
United States locations
- U.S. sites
- 59
- U.S. states
- 27
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Anchorage | Alaska | 99503 | — |
| Not listed | Gilbert | Arizona | 85234 | — |
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Duarte | California | 91010 | — |
| Not listed | La Jolla | California | 92093 | — |
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Vallejo | California | 94589 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Denver | Colorado | 80218 | — |
| Not listed | New Haven | Connecticut | 06520 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Boca Raton | Florida | 33486 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Miami | Florida | 33176 | — |
| Not listed | Orlando | Florida | 06520 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Westwood | Kansas | 66205 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Baltimore | Maryland | 21287 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | Albany | New York | 12206 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Durham | North Carolina | 22710 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Portland | Oregon | 97213 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Philadelphia | Pennsylvania | 19111 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Knoxville | Tennessee | 37920 | — |
| Not listed | Memphis | Tennessee | 38120 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Austin | Texas | 78731 | — |
| Not listed | Bedford | Texas | 76022 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Houston | Texas | 77024 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Salt Lake City | Utah | 84112 | — |
| Not listed | Seattle | Washington | 98109 | — |
| Not listed | Vancouver | Washington | 98684 | — |
| Not listed | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 146 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01865747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01865747 live on ClinicalTrials.gov.